Doximity Inc Cl A (DOCS) Stock Price, Quote & News

Company Profile

Doximity, Inc. operates as a digital platform for medical professionals in the United States. Its platform provides its members with digital tools built for medicine, that enables its members to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The company primarily serves physicians, nurse practitioners, physician assistants...

Industry: Health Information Services

Sector: Healthcare

Phone: 650 549 4330

Website: www.doximity.com

Address:

500 3rd Street, Suite 510, San Francisco, United States

mikesterz7 Nov. 16 at 3:31 PM

$DOCS Bank of Montreal Can Sells 49,807 Shares of Doximity, Inc.

0 · Reply

GetOverHere_ Nov. 14 at 8:51 AM

$ECDA $DOCS $GCT $GLBE <

0 · Reply

JarvisFlow Nov. 13 at 9:38 AM

BMO Capital has adjusted their stance on Doximity ( $DOCS ), setting the rating to Market Perform with a target price of 55.

0 · Reply

SuperGreenToday Nov. 12 at 6:13 PM

$DOCS Share Price: $51.46 Contract Selected: Feb 20, 2026 $50 Calls Buy Zone: $5.44 – $6.72 Target Zone: $9.03 – $11.03 Potential Upside: 57% ROI Time to Expiration: 99 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

justretire Nov. 12 at 4:42 PM

$DOCS Founder Dr. Nate Gross left Doximity for OpenAI

1 · Reply

Walkadon Nov. 12 at 3:54 AM

$DOCS Alot of headwinds here. Great company and balance sheet but sketchy outlook. Technically weak for last several weeks Cautious forward looking earnings comments (uncertainty) Peers and sectors following suit in weakness Last 2 quarter reports were good, but reaction worsened each time more severely in succession. Alot of headlines and concern of how Trump Care and Trump RX will affect the medical insurance pharma space, already shaking up some big pharma drugs ie: weight loss If big pharma can have Trump market their special deals, why advertise anywhere else? 2 pending lawsuits advancing through the courts that will likely be nothingburgers imho, but creates anxiety having them pending. Great company, great performance, great balance sheet and financial stewardship, but a difficult and perhaps choppy hold until some of this clears. Especially with markets gaining momentum and full of opportunities.

0 · Reply

Pktitu Nov. 11 at 4:33 PM

$AMWL $TDOC $HIMS $DOCS Amwell (AMWL) holds $200 million in cash, carries no debt, and generates about $250 million in annual revenue, yet its market cap has collapsed to around $60 million. In the past five days alone, the company’s market cap fell from about $85M to $64M—a $21M.X drop (25%)—on only 150K shares traded daily, about $600K a day. That means $3M in total trading wiped out $21M.X in market value — every $1 traded erased roughly $7 of company value. These moves clearly reflect thin liquidity and possible price manipulation, not weak fundamentals.

0 · Reply

JarvisFlow Nov. 10 at 8:29 PM

Canaccord Genuity updates rating for Doximity ( $DOCS ) to Hold, target set at 67 → 58.

0 · Reply

Walkadon Nov. 8 at 9:54 PM

$DOCS Yeah, if ACA deal is not extended all the easy money from your fellow citizens will not be going to big pharma and healthcare companies, so less advertising gravy to throw around. Maybe that is what she was referring to, with that being right in the middle of the gov. shutdown discussions.

0 · Reply

Walkadon Nov. 8 at 3:13 PM

$DOCS Stock did not fall because of short hit piece, stock fell from overall poor market risk off sentiment in a beaten up sector and some cautionary commentary from CFO in opening statements of call as follows imho: "At the same time, client discussions suggest some uncertainty over how recent policy changes may influence annual budgets, which are expected to be finalized over the next 2 months. As a result, we will continue to take a measured approach to the revenue we have yet to book, which is reflected in our implied Q4 guidance." If you haven't noticed this is the new normal for equities, constant chaos and uncertainty. If you cannot handle risk you shouldn't be invested in no par value or little par value equity (common stock), it trade on pure future speculation of events to come. Markets do not like uncertainty and will trade accordingly until said uncertainty clears. Furthermore, read SEC filings and Safe Harbor Statement, it is there for a reason.

0 · Reply

Doximity, Inc. (DOCS) Q2 2026 Earnings Call Transcript

Nov 6, 2025, 4:01 PM EST - 10 days ago

Doximity Announces Fiscal 2026 Second Quarter Financial Results

Oct 24, 2025, 7:40 AM EDT - 23 days ago

Halper Sadeh LLC Encourages Doximity Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 16, 2025, 4:01 PM EDT - 4 weeks ago

Doximity to Release Fiscal 2026 Second Quarter Results on November 6, 2025

Oct 1, 2025, 5:30 PM EDT - 6 weeks ago

Doximity, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Aug 8, 2025, 11:21 AM EDT - 3 months ago

Doximity Analysts Increase Their Forecasts After Strong Q1 Earnings

Aug 7, 2025, 9:50 PM EDT - 3 months ago

Doximity, Inc. (DOCS) Q1 2026 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 3 months ago

Doximity buys Pathway Medical for $63 million to help doctors get AI-powered answers

Aug 7, 2025, 4:02 PM EDT - 3 months ago

Doximity Acquires Pathway, a Leader in AI Clinical Reference

Aug 7, 2025, 4:01 PM EDT - 3 months ago

Doximity Announces Fiscal 2026 First Quarter Financial Results

Jul 31, 2025, 5:00 AM EDT - 3 months ago

New Doximity Study Shows Modest Physician Pay Growth Amid Deeper Workforce Strain, Reimbursement Pressures

Jul 23, 2025, 3:35 PM EDT - 4 months ago

Doximity: Slowing Sales And EBITDA Growth

Jul 17, 2025, 4:01 PM EDT - 4 months ago

Doximity to Release Fiscal 2026 First Quarter Results on August 7, 2025

Jul 2, 2025, 10:36 AM EDT - 4 months ago

Doximity Crushes The Rule Of 40 - Try Rule Of 58

Jun 18, 2025, 7:18 AM EDT - 5 months ago

Doximity: A Unique, Debt-Free Healthcare-Tech Platform, Initiate With 'Buy'

May 21, 2025, 4:01 PM EDT - 6 months ago

Doximity to Present at the William Blair 45th Annual Growth Stock Conference

May 19, 2025, 7:47 AM EDT - 6 months ago

Doximity Stock 7.8% Higher After Key Trading Signal

May 16, 2025, 1:51 PM EDT - 6 months ago

These Analysts Cut Their Forecasts On Doximity After Q4 Results

May 16, 2025, 9:09 AM EDT - 6 months ago

Globant, Doximity, Applied Materials And Other Big Stocks Moving Lower In Friday's Pre-Market Session

AMAT GLOB

May 15, 2025, 8:35 PM EDT - 6 months ago

Doximity, Inc. (DOCS) Q4 2025 Earnings Call Transcript

May 15, 2025, 5:55 PM EDT - 6 months ago

Doximity Stock Drops 20% After Outlook Disappoints

May 15, 2025, 4:01 PM EDT - 6 months ago

Doximity Announces Fourth Quarter and Fiscal Year 2025 Financial Results

May 1, 2025, 9:23 AM EDT - 7 months ago

Doximity: Strong Fundamentals And Pharma Tailwinds Meet An Overpriced Valuation

Apr 24, 2025, 4:01 PM EDT - 7 months ago

Doximity to Release Fiscal 2025 Fourth Quarter and Full Year Results on May 15, 2025

Feb 21, 2025, 9:00 AM EST - 9 months ago

DOXIMITY INVESTOR REMINDER: Scott+Scott Attorneys at Law LLP Investigates Doximity, Inc.'s Directors and Officers for Breach of Fiduciary Duties – DOCS

Feb 14, 2025, 5:53 PM EST - 9 months ago

Doximity: Rating Downgrade As Near-Term Upside Is Priced In

Feb 14, 2025, 7:49 AM EST - 9 months ago

Doximity Momentum, Big Money Support Stays Strong

Feb 13, 2025, 4:29 PM EST - 9 months ago

Doximity to Participate in the Raymond James 46th Annual Institutional Investors Conference

Feb 10, 2025, 12:04 PM EST - 9 months ago

Doximity Q3 Earnings: Outpacing Even Management's Expectations

Feb 7, 2025, 1:24 PM EST - 10 months ago

Digital Health Platform Doximity Stock Jumps On Upbeat Annual Outlook, Analysts Raise Forecast

Feb 7, 2025, 10:38 AM EST - 10 months ago

Doximity shares pop 30% on revenue beat, rosy guidance

Feb 6, 2025, 8:01 PM EST - 10 months ago

Doximity, Inc. (DOCS) Q3 2025 Earnings Call Transcript

Feb 6, 2025, 5:14 PM EST - 10 months ago

Doximity shares soar 21% after company beats on revenue, raises fiscal year guidance

Feb 6, 2025, 4:02 PM EST - 10 months ago

Doximity Ranked #1 Best in KLAS Telehealth Video Platform for Fourth Consecutive Year

Feb 6, 2025, 4:01 PM EST - 10 months ago

Doximity Announces Fiscal 2025 Third Quarter Financial Results

Jan 16, 2025, 4:01 PM EST - 10 months ago

Doximity to Release Fiscal 2025 Third Quarter Results on February 6, 2025

Jan 13, 2025, 6:51 AM EST - 10 months ago

Doximity: Upgraded To Buy Amid Promising Growth And Strong Execution

Jan 7, 2025, 8:00 AM EST - 11 months ago

Stock Picks From Seeking Alpha's December 2024 New Analysts

ALGM CE CEG ETD FDVV FSS HOG

Dec 24, 2024, 8:00 AM EST - 11 months ago

Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown

DXCM GDRX HIMS OSCR PGNY TDOC TEM

Dec 17, 2024, 8:00 AM EST - 11 months ago

Doximity Report Confirms That Telemedicine Serves Key Role in Modern Health Care

Dec 6, 2024, 7:52 AM EST - 1 year ago

Doximity: Strong Fundamentals And Growth Potential Makes It Attractive

Nov 15, 2024, 8:00 AM EST - 1 year ago

Doximity Q2 Earnings: Positioning Is Paying Off

Nov 8, 2024, 8:45 AM EST - 1 year ago

Why Doximity Stock is Set to Open at Highest Point in Over 2 Years Friday

Nov 8, 2024, 8:03 AM EST - 1 year ago

Doximity Stock Soars 42% Toward Best Day Ever. It's Not the Only Record.

Nov 7, 2024, 10:07 PM EST - 1 year ago

Doximity, Inc. (DOCS) Q2 2025 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 1 year ago

Doximity Announces Fiscal 2025 Second Quarter Financial Results

Oct 31, 2024, 4:01 PM EDT - 1 year ago

Doximity to Present at the Jefferies London Healthcare Conference

Oct 17, 2024, 4:01 PM EDT - 1 year ago

Doximity to Release Fiscal 2025 Second Quarter Results on November 7, 2024

Oct 15, 2024, 4:50 PM EDT - 1 year ago

Overlooked Stock: DOCS

mikesterz7 Nov. 16 at 3:31 PM

$DOCS Bank of Montreal Can Sells 49,807 Shares of Doximity, Inc.

0 · Reply

GetOverHere_ Nov. 14 at 8:51 AM

$ECDA $DOCS $GCT $GLBE <

0 · Reply

JarvisFlow Nov. 13 at 9:38 AM

BMO Capital has adjusted their stance on Doximity ( $DOCS ), setting the rating to Market Perform with a target price of 55.

0 · Reply

SuperGreenToday Nov. 12 at 6:13 PM

0 · Reply

justretire Nov. 12 at 4:42 PM

$DOCS Founder Dr. Nate Gross left Doximity for OpenAI

1 · Reply

Walkadon Nov. 12 at 3:54 AM

0 · Reply

Pktitu Nov. 11 at 4:33 PM

0 · Reply

JarvisFlow Nov. 10 at 8:29 PM

Canaccord Genuity updates rating for Doximity ( $DOCS ) to Hold, target set at 67 → 58.

0 · Reply

Walkadon Nov. 8 at 9:54 PM

0 · Reply

Walkadon Nov. 8 at 3:13 PM

0 · Reply

Walkadon Nov. 7 at 8:10 PM

$DOCS From Zacs Research Earnings Commentary below: Doximity’s Financial Position Doximity exited second-quarter fiscal 2026 with cash and cash equivalents of $169.2 million compared with $137.3 million at the fiscal first-quarter end. Cumulative net cash provided by operating activities at the end of second-quarter fiscal 2026 was $156 million compared with $109.6 million a year ago. GUYS, MY MATH SAYS THEY HAVE OVER 900 MILLION IN CASH TODAY !!!

0 · Reply

justretire Nov. 7 at 7:27 PM

$DOCS Not good. Written by a MD: https://open.substack.com/pub/kianimd/p/the-117b-dialer-what-doximity-reveals?r=2cgzi7&utm_medium=ios

2 · Reply

fadedtrader Nov. 7 at 7:13 PM

$DOCS my old friend, hoping to add a starter at $53.50 but prepared to scoop lower if needed.

0 · Reply

ZacksResearch Nov. 7 at 6:13 PM

$DOCS crushed Q2 earnings, yet shares are down 8.9% pre-market. What’s happening? 🤔 📈 Adjusted EPS up 50% YoY, beating estimates by 18.4% 💰 Revenue up 23.2%, surpassing forecasts by 6.8% 💡 AI-driven product updates and strong engagement metrics Discover what’s driving the sell-off despite strong results 👉 https://www.zacks.com/stock/news/2788050/doximity-stock-down-despite-q2-earnings-beat-revenues-up-yy?cid=sm-stocktwits-2-2788050-body-20162&ADID=SYND_STOCKTWITS_TWEET_2_2788050_BODY_20162

0 · Reply

ZacksResearch Nov. 7 at 5:13 PM

$DOCS crushed Q2 earnings and grew revenue year over year — yet the stock’s down nearly 9% pre-market 😮 Even with rising AI-driven engagement fueling results, investors aren’t buying the strength just yet. See what’s behind the sell-off here 👉 https://www.zacks.com/stock/news/2788050/doximity-stock-down-despite-q2-earnings-beat-revenues-up-yy?cid=sm-stocktwits-2-2788050-teaser-20119&ADID=SYND_STOCKTWITS_TWEET_2_2788050_TEASER_20119

0 · Reply

justretire Nov. 7 at 4:26 PM

$DOCS wow wheels off, the lawsuit is going to be very bad

0 · Reply

DARKP00L Nov. 7 at 2:26 PM

$DOCS 09:18 on Nov. 07 2025 Evercore ISI Group Maintains Outperform on Doximity, Lowers Price Target to $70 #tradeideas

0 · Reply

JarvisFlow Nov. 7 at 2:18 PM

Evercore ISI Group has updated their rating for Doximity ( $DOCS ) to Outperform with a price target of 70.

0 · Reply

d_risk Nov. 7 at 12:13 AM

$DOCS - Doximity Inc. Class A Common Stock - 10Q - Updated Risk Factors DOCS flags new risks: potential litigation exposure and challenges in managing or integrating acquisitions and investments could materially impact business and financial results. #HealthcareTechnology #FinancialImpact #AcquisitionChallenges #LitigationRisk 🟢 Added 🟠 Removed https://d-risk.ai/DOCS/10-Q/2025-11-06

1 · Reply

Walkadon Nov. 6 at 11:34 PM

$DOCS If you have not been looking lately, beat top, bottom and raise guidance gets you a selloff. Market has changed but DOCS continues to do the same thing, under promise and over deliver across the board. Be patient folks.

0 · Reply

CarloNoS Nov. 6 at 10:26 PM

$DOCS same as last time. Down on good earnings but in a weird market. Low volume stock that acts this way AH. I expect a strong bounce tomorrow and into next week.

0 · Reply

Huck18 Nov. 6 at 9:54 PM

$DOCS Rev. Growth for the FYE 27, is only 11%+, so is EPS Growth (10.5%), that's Abysmal ... For a 37 PE ...

0 · Reply

Market Cap	9.34B
Revenue (ttm)	570.40M
Net Income (ttm)	223.19M
EPS (ttm)	N/A
PE Ratio	38.54
Forward PE	44.56
Profit Margin	39.13%
Debt to Equity Ratio	0.00

Volume	2,369,600
Avg Vol	1,556,572
Day's Range	N/A - N/A
Shares Out	188.27M
Stochastic %K	3%
Beta	1.36
Analysts	Sell
Price Target	$69.05